IT raids at Hyderabad-based pharma group, Rs 400 crore Black income detected: CBDT

Published On 2021-03-02 07:46 GMT   |   Update On 2021-03-02 10:23 GMT
Advertisement

New Delhi: The Income Tax Department has detected "unaccounted" income of about Rs 400 crore after raids on a major pharmaceutical group based in Hyderabad, the Central Board of Direct Taxes (CBDT) said on Monday. The searches were carried out on February 24 at around 20 locations spread across five states.

The CBDT said the pharmaceutical group is engaged in the business of manufacturing of intermediates, active pharmaceutical ingredients (APIs) and formulations, and majority of its products are exported to European countries and the USA.
"The search has led to unearthing of evidence relating to unaccounted income of around Rs 400 crore, out of which the assessee group has admitted an additional income of Rs 350 crore," the CBDT claimed in a statement.
It added that Rs 1.66 crore cash was also seized during the operation.
"Incriminating evidence in the form of digital media, pen drives, documents, etc. have been found and seized," the CBDT said.
The statement said digital evidences were gathered from SAP-ERP software.
"Issues relating to purchases made from bogus and non-existent entities, artificial inflation of certain heads of expenditure, alongwith suppression of receipts relating to by-product sale were detected.
"Evidence of on-money payment for purchase of lands was also found," it alleged.
Multiple other legal issues were also identified such as personal expenses being booked in the company's books and land purchased by related concerns or individuals below government value, the CBDT said.

Read also: Illegal diversion, supply of neuro-psychotropic drugs alprazolam, cough syrups busted in MP, 3 arrested



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News